Categories: News

Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer

Recent Posts

Think Together Expands Executive Team with Matt Scharpnick as Chief of Innovation

Think Together creates new C-suite role to fuel market innovation and transform educational outcomes as…

2 hours ago

MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch AGI-Powered Diagnostic Intelligence Across Pakistan

ISLAMABAD, May 22, 2025 /PRNewswire/ -- In a groundbreaking move to elevate clinical diagnostics nationwide,…

2 hours ago

Hexaware Accelerates Delivery Solutions with a New Office in Chicago

CHICAGO, May 22, 2025 /PRNewswire/ -- Hexaware Technologies (NSE: HEXT), a leading global IT services…

8 hours ago

Bulletin from the Annual General Meeting 2025

The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025,…

8 hours ago

Lofta and Bloom Mental Health Partner to Bridge the Gap Between Sleep Apnea and Mental Health

SAN DIEGO, May 22, 2025 /PRNewswire/ -- Lofta, a leader in at-home sleep apnea testing…

8 hours ago

AMA Establishes CPT Codes for Minimally Invasive ESD Procedure

CENTER VALLEY, Pa., May 22, 2025 /PRNewswire/ -- Olympus Corporation, a global medical technology company…

8 hours ago